Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.45.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-1.23
EARNINGS PER SHARE (EPS) AVG 3Y
N/A
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Attovia Therapeutics, Inc.
Market Cap
$774.32M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.72M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
Market Cap
$776.24M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
Market Cap
$780.95M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
Market Cap
$767.46M
Earnings Per Share (EPS)
-4.74
TTM Avg
-5.08
3Y Avg
-296.60
5Y Avg
-1006.80
Market Cap
$786.48M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.28
3Y Avg
-0.16
5Y Avg
-0.10
Market Cap
$749.55M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$734.10M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $774.32M | N/A | -1.23 | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -1.18 | -1.05 | -1.11 | -0.92 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -1.68 | 0.05 | -1.18 | -0.72 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -4.74 | -5.08 | -296.60 | -1006.80 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -0.62 | -0.28 | -0.16 | -0.10 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -1.41 | -1.23 | -0.97 | -1.16 |
| InMode Ltd. (INMD)vs › | $812.20M | 1.23 | 1.87 | 2.02 | 1.86 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -2.76 | -3.16 | -2.11 | -1.54 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -0.20 | 0.10 | -0.30 | -1.16 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-4.06
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.42 |
| 2024-12-31 | -1.05 |
